Monopar Therapeutics (MNPR) R&D In Process (2017)
Quarterly results put R&D In Process at $14.5 million for Q3 2017, changed N/A from a year ago — trailing twelve months through Dec 2018 was $14.5 million (changed N/A YoY), and the annual figure for FY2017 was $14.5 million, changed.
Monopar Therapeutics has reported R&D In Process over the past 1 years, most recently at $14.5 million for Q3 2017.
- R&D In Process reached $14.5 million in Q3 2017 per MNPR's latest filing.
- Across five years, R&D In Process topped out at $14.5 million in Q3 2017 and bottomed at $14.5 million in Q3 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 500,000.00 |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 101.90 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 14.50 Mn |